Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis' (NVS) asthma candidate, fevipiprant, fails to meet endpoint in the phase III LUSTER studies.

Novartis' Asthma Candidate Fails in LUSTER Phase III Studies

Novartis (NVS) obtains positive CHMP opinion for its wet AMD drug Beovu. A potential approval will boost its ophthalmology franchise.

Novartis Gets Positive CHMP Opinion for Wet AMD Drug Beovu

AbbVie

Allergan

Bristol-Myers

Celgene

Eli Lilly

Medicines

Merck

Pfizer

Sanofi

Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.

Biotech Stocks Burn A Hole In Big Pharma's Pocket. Look For More In 2020

Novartis (NVS) closed the most recent trading day at $93.06, moving +0.02% from the previous trading session.

Novartis (NVS) Gains But Lags Market: What You Should Know

Alector Inc

Amarin Corporation Plc

Athenex

Biohaven Pharmaceutical Hld

Cara Therapeutics

Global Blood Therapeutics

Intra-Cellular Therapies

Puma Biotechnology

Protagonist Therapeutics

Proteostasis Therapeutics

Rocket Pharma

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Biotech’s Year-End To-Do List

Terrific clinical trial data followed by a $9.7 billion buyout offer gave investors lots to be thankful for.

Here's Why The Medicines Company Jumped 60% in November

Alnylam Pharmaceuticals

BeiGene

Vertex Pharmaceuticals

Here's why the FDA recently approved five new drugs way ahead of schedule.

5 New Drug Approvals the FDA Gave Top Priority

Swiss drugmaker Novartis's  new $90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of treatments, including Kymriah for cancer and Zolgensma for spinal muscular atrophy, in 2020.

Novartis's $90 million Swiss factory to help solve cell therapy bottleneck

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.

Pfizer, Novartis lead $2 billion spending spree on gene therapy production

Pfizer, Novartis lead pharma spending spree on gene therapy production

Novartis' Latest Acquisition Of The Medicines Company Sets It Up For A Large Market

VanEck Vectors Biotech ETF

CRISPR Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.

Why Biotech ETFs Surged in Monday's Trading Session

Editas Medicine

Intellia Therapeutics

There’s still a long way to go, but the newcomer is off to a good start.

CRISPR vs. Gene Therapy Round 1: What Investors Need to Know

One drug is at the center of the deal: inclisiran. Here is what it does and what RNA interference is.

Why Novartis Is Buying The Medicines Company For $9.7 Billion

Biotechnology ETFs led the charge on Monday after Novartis AG (NYSE: NVG) agreed to buy Medicine Co. (NasdaqGS: MDCO) as the Swiss multinational pharmaceutical company moves to expand its treatment for complex conditions.

Biotech ETFs Pop After Novartis Acquires Medicines Co.

The Medicines Company (MDCO) news for Monday about a $9.70 billion deal with Novartis (NVS) has MDCO stock heading higher.
The post The Medicines Company News: MDCO Stock Rockets 22% on Novartis Deal appeared first on InvestorPlace.

The Medicines Company News: MDCO Stock Rockets 22% on Novartis Deal

Understanding why can help you identify the next takeout target.

A 45% Premium: Here's Why The Medicines Company Is Worth More to Novartis Than It Was to You

Shares of RNA interference biotech companies surged Monday after Novartis announced its $9.7 billion takeover of The Medicines Company, adding a promising cholesterol drug to its wheelhouse.
The post Novartis' Takeover Of Medicines Puts The Spotlight On These Biotechs appeared first on Investor's Business Daily.

Novartis' Takeover Of Medicines Puts The Spotlight On These Biotechs

AMTD International Inc

LVMH Moet Hennessy Louis Vuitton

Charles Schwab

Tiffany & Co.

While Tiffany's agrees to terms with French luxury brand LVMH, Schwab buys Ameritrade, Novartis takes Medicines Co. and more.

Biggest Merger Monday in Awhile: TIF, AMTD, MDCO & More

Medicines Co. (NASDAQ: MDCO) shares shot up on Monday after it was reported that Novartis A.G.

Novartis Finally Comes Through With Its Acquisition of Medicines Co

Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.

Novartis (NVS) to Acquire The Medicines Company for $9.7B

The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.

The Medicines Company to be Acquired by Novartis for $9.7B

Following reports last week, Novartis AG (NYSE: NVS) confirmed on Monday a deal to acquire the Medicines Company (NASDAQ: MDCO) for $9.7 billion, or $85 per share.

Novartis Confirms Deal To Acquire Medicines Company For $9.7B

Happy Monday. A version of this story first appeared in CNN Business' Before the Bell newsletter. Not a subscriber? You can sign up right here.

Merger Monday: Three major deals and one that could turn hostile

Novartis AG agreed to buy Medicines Co. for about $6.8 billion, snapping up a promising cholesterol drug and adding to a string of recent acquisitions for Chief Executive Officer Vas.

Novartis To Buy Medicines Co. In $6.8 Billion Deal For Key Drug

News for Novartis Stock (NVS)